Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Aiforia provides advanced deep learning and cloud-based solutions to pathologists and researchers in both preclinical and clinical laboratories, enhancing their capabilities in image analysis and workflow efficiency. By enabling scientists to discover new disease biomarkers and assisting R&D professionals in accelerating the market introduction of innovative drugs, Aiforia plays a crucial role in improving cancer diagnostic accuracy while revolutionizing healthcare from the initial discovery phase through to diagnosis. For clinical pathology laboratories seeking to boost efficiency and elevate the precision of their diagnoses, the Aiforia Clinical Suites present a comprehensive range of AI-driven diagnostic tools, intelligent visualization, quality control, and automated pre- and post-screening functionalities. We are in the process of developing specialized Suites targeting some of the most common cancers globally and have achieved CE-IVD certification for our AI solutions in lung and breast cancer, positioning us as a leader in diagnostic innovation. Our commitment to enhancing patient outcomes through technology underscores the transformative potential of our offerings in the healthcare sector.
Description
AI plays a crucial role in identifying early-stage cancers, facilitating prompt interventions that enhance survival prospects. Cancer's intricate nature means that each type carries distinct characteristics, packed with extensive data that requires thorough analysis. This is where AI excels, leveraging its capabilities to process complex information, ultimately revealing insights that can significantly aid in cancer treatment strategies. Equipped with precise and relevant data, we take proactive steps in our battle against cancer. By utilizing AI, we are poised to make substantial strides in overcoming this disease. Our AI technology is designed to detect early-stage cancer with remarkable accuracy, achieving detection rates between 97-99%. It proficiently identifies ten of the most prevalent abnormalities found in chest x-rays, thus enhancing one of the most fundamental diagnostic tools. This innovation not only streamlines the radiology workflow but also alleviates the workload for radiologists. Lunit INSIGHT CXR successfully encompasses a wide range of findings, ensuring that we are prepared to tackle the challenges presented by cancer detection and treatment. The future of cancer care looks promising with AI at the forefront of these advancements.
API Access
Has API
No
API Access
Has API
No
Integrations
Charles River IMS
No
Microsoft 365
No
NVIDIA DRIVE
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
Yes
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
Yes
Vendor Details
Company Name
Aiforia
Country
United States
Website
www.aiforia.com
Vendor Details
Company Name
Lunit
Country
United States
Website
www.lunit.io/en